Proteotech And Tasly Pharmaceuticals Announce Alzheimer's Disease Drug Developme

< BACK TO DEFENCE starstarstarstarstar   Government - Defence Press Release
5th October 2010, 02:15am - Views: 893

Misc Miscellaneous ProteoTech Inc. 2 image


ProteoTech and Tasly Pharmaceuticals Announce Alzheimer's Disease Drug Development

Agreement for Exebryl-1(R)

KIRKLAND, Wash., Oct. 4 /PRNewswire-AsiaNet/ --

           Potential disease-modifying Alzheimer's treatment targeting

    beta-amyloid and tau protein advancing through collaboration between

      ProteoTech Inc. and major Chinese company, Tasly Pharmaceuticals.

    Tasly Pharmaceutical Co., Ltd. (Tianjin, China) and ProteoTech, Inc.

(Kirkland, WA, USA) today announced an agreement to co-develop ProteoTech's

novel small molecule therapeutic, Exebryl-1(R), for the treatment of

mild-to-moderate Alzheimer's disease. Exebryl-1(R) has been shown to inhibit

beta-amyloid protein aggregate formation in brain, as well as disaggregate

amyloid plaques that are already present. The drug has also shown specificity

against tau protein aggregates and may be the first therapeutic targeting

beta-amyloid and tau protein associated with this disease.

    The collaboration will focus on moving the clinical development of this

drug though the regulatory process in China and the US. Terms of the deal

were not disclosed but will include an upfront payment, development costs and

research funding to ProteoTech according to Manuel Menendez, Managing Partner

of Nobel Pacific, who acted as an advisor to both companies. Tasly will gain

rights for Exebryl-1(R) for China and ProteoTech will retain rights for the

United States and the rest of the world.

    "We are very happy with this opportunity to work with the team at

ProteoTech and we feel that Exebryl-1(R) will become a very important

medication in China against the growing epidemic of Alzheimer's disease"

stated Dr. Henry Sun, Vice President of Tasly Group and President of Tasly

Pharmaceuticals, Inc.

    ProteoTech CEO, Steve Runnels said "The opportunity for this

collaboration with a major international pharmaceutical company is very

exciting for us. We are very fortunate to have Tasly as a partner and their

experience in drug development, especially in China, provides an opportunity

to accelerate Exebryl-1(R) through clinical development. We look forward to a

successful Exebryl-1(R) collaboration with Tasly and the potential

development of other promising technologies in our pipeline as well."

    About ProteoTech: ProteoTech is a private drug development company in

Kirkland, WA and is focused on targeting amyloid diseases. Besides

Exebryl-1(R) for Alzheimer's disease treatment, the Company is also in late

stage pre-clinical development of Synuclere(TM) 

Parkinson's disease, Systebryl(TM) 

Systemic Amyloidosis, and is in late stage pre-clinical development for a

novel small peptide called PeptiClere(TM) 

Alzheimer's disease. For more information please see the Company web site at

To view this and other AsiaNet releases please visit

    About Tasly: Tasly was founded in May 1994 in Tianjin, China. With the

pharmaceutical industry as its center, Tasly has become a leading group of

high technology companies, whose scope of business includes modern TCM,

ethical pharmaceutical and biological medications, healthcare products and

functional foods covering the fields of research and development,

manufacturing and distribution. Trading on the Shanghai Stock Exchange

(#600535), Tasly has consistently kept true to the core values of adding to

shareholder value as well as social responsibility and philanthropy. For more

information please see the company web site at

    SOURCE:  ProteoTech Inc.

    CONTACT: Steve Runnels, 

             +1-425-823-0400, Ext. 16, 



news articles logo NEWS ARTICLES
Contact News Articles |Remove this article